Collectively, the findings support our previous 5-day study (42) and other in vivo animal studies demonstrating increased intestinal mucosal growth after parenteral (65) and especially oral IGF-1 administration (35, 36, 66, 67), as well as the reduced NEC incidence in a rodent study (68). This evidence concerns the gene IGF1 and necrotizing enterocolitis.